Mubasher: The US has reached an agreement with biotech company Moderna Inc to purchase 100 million doses of its potential coronavirus (COVID-19) vaccine for about $1.5 billion, Reuters reported in the early hours of Wednesday.
Moderna’s vaccine candidate, mRNA-1273, is priced at about $30.50 per person for a two-dose course of treatment and is one of the few that advanced to the final stage of testing, expected to be completed in September.
Over the last few months, the US has made several deals to acquire hundreds of millions of doses of COVID-19 vaccine candidates with other companies such as Johnson & Johnson, AstraZeneca, Pfizer, BioNTech, Sanofi, and GlaxoSmithKline.
All agreements price COVID-19 vaccines between $20 and $42 per a two-dose regimen, except for AstraZeneca which offered a lower price in exchange for upfront research and development costs.
The number of confirmed COVID-19 cases in the US reached 5.309 million, including 2.757 million recoveries and 167,789 deaths.